Heron Therapeutics, Inc.
HRTXHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 12
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. With a market capitalization of $182.5M, it sits in micro-cap territory. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Market Cap
$182.5M
Beta
1.71
P/E (TTM)
—
P/E (Fwd)
1.89
EPS (TTM)
$-0.18
EPS (Fwd)
$0.00
ROE
—
ROA
-2.7%
Cash
$44.8M
Total Debt
$141.6M
Free CF
-$18.4M
52W Change
-44.2%
Annual Financials
Cash vs Debt
Where HRTX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, HRTX finished 17.24% below its 150-day moving average ($1.16) and 21.31% below its 200-day moving average ($1.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HRTX overbought or oversold?
At the July 15, 2026 close, HRTX's RSI(14) was 46.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Heron Therapeutics, Inc. carries $141.6M in total debt against $44.8M in cash reserves — debt is roughly 3.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$18.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $107.7M (2022) to $154.9M (2025), reflecting a 44% increase over the period.
A beta of 1.71 means HRTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HRTX.